# Empagliflozin in Post-Transplantation Diabetes Mellitus

> **NCT03113110** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 16 (estimated)

## Conditions studied

- Posttransplant Diabetes Mellitus

## Interventions

- **DRUG:** Empagliflozin 10 mg

## Key facts

- **NCT ID:** NCT03113110
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-15
- **Primary completion:** 2017-06-13
- **Final completion:** 2018-05-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2019-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113110, "Empagliflozin in Post-Transplantation Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03113110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*